Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Investors, Beware Of The False Positive

This article was originally published in Scrip

Executive Summary

On the cusp of third-quarter earnings season and after nine weeks of an often savage stock market sell-off, the market bounced last week. With algorithmic trading and dark pools influencing the volume and prices of shares traded in the more opaque portions of the stock market, a three-day market bounce might be as believable as the official figures on the growth of the Chinese economy.

You may also be interested in...



Biosimilars: The Unlikely Hero Of Specialty Pharma?

In the patent cliff musical chairs game, the music has stopped and generic companies like Mylan and Teva are looking for the next growth driver. While this seems to be biosimilars, it appears that innovator companies who are used to developing biologics, are already sitting in their seats.

Biosimilars: The Unlikely Hero Of Specialty Pharma?

In the patent cliff musical chairs game, the music has stopped and generic companies like Mylan and Teva are looking for the next growth driver. While this seems to be biosimilars, it appears that innovator companies who are used to developing biologics, are already sitting in their seats.

Stockwatch: Hopes For Fireworks But Expectations For Goldilocks

With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029956

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel